J
J. Thaddeus Beck
Researcher at University of Erlangen-Nuremberg
Publications - 92
Citations - 7402
J. Thaddeus Beck is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 72 publications receiving 6041 citations. Previous affiliations of J. Thaddeus Beck include University of North Florida.
Papers
More filters
Journal ArticleDOI
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga,Mario Campone,Martine Piccart,Howard A. Burris,Hope S. Rugo,Tarek Sahmoud,Shinzaburo Noguchi,Michael Gnant,Kathleen I. Pritchard,Fabienne Lebrun,J. Thaddeus Beck,Yoshinori Ito,Denise A. Yardley,Ines Deleu,Alejandra T. Perez,Thomas Bachelot,L. Vittori,Zhiying Xu,Pabak Mukhopadhyay,David Lebwohl,Gabriel N. Hortobagyi +20 more
TL;DR: Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors.
Journal ArticleDOI
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon,Patrick Neven,Stephen Chia,Peter A. Fasching,Michelino De Laurentiis,Seock-Ah Im,K. Petrakova,Giulia Val Bianchi,Francisco J. Esteva,Miguel Martin,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz-Merino,J. Thaddeus Beck,Xavier Pivot,Gena Vidam,Yingbo Wang,Karen Rodriguez Lorenc,Michelle Miller,Tetiana Taran,Guy Jerusalem +20 more
TL;DR: Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Journal ArticleDOI
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto,Dirk Schadendorf,Carola Berking,Sanjiv S. Agarwala,Carla M.L. van Herpen,Paola Queirolo,Christian U. Blank,Axel Hauschild,J. Thaddeus Beck,Annie St-Pierre,Faiz Niazi,Simon Wandel,Malte Peters,Angela Zubel,Reinhard Dummer +14 more
TL;DR: MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.
Journal ArticleDOI
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E. Goss,James N. Ingle,Kathleen I. Pritchard,Nicholas J. Robert,Hyman B. Muss,Julie R. Gralow,Karen A. Gelmon,Timothy J. Whelan,Kathrin Strasser-Weippl,Sheldon Rubin,Keren Sturtz,Antonio C. Wolff,Eric P. Winer,Clifford A. Hudis,Alison Stopeck,J. Thaddeus Beck,Judith S. Kaur,Kate Whelan,Dongsheng Tu,Wendy R. Parulekar +19 more
TL;DR: The extension of treatment with an adjuvant aromatase inhibitor to 10 years resulted in significantly higher rates of disease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but the rate of overall survival was not higher with the aromat enzyme inhibitor than with placebo.
Journal ArticleDOI
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Dennis J. Slamon,Patrick Neven,Stephen Chia,Peter A. Fasching,Michelino De Laurentiis,Seock-Ah Im,K. Petrakova,Giulia Val Bianchi,Francisco J. Esteva,Miguel Martin,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz-Merino,J. Thaddeus Beck,Xavier Pivot,Manu Sondhi,Yingbo Wang,Arunava Chakravartty,Karen Rodriguez-Lorenc,Tetiana Taran,Guy Jerusalem +20 more
TL;DR: In this paper, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrants alone in postmenopaugmentation.